Cases of recurrence of clinical symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after completion of treatment with nirmatrelvir–ritonavir have been reported by researchers 1 ...

Real-world data on the effects of nirmatrelvir/ritonavir can be used to counsel patients. Nirmatrelvir/ritonavir (Paxlovid) reduces the risks for hospitalization and death in patients with COVID-19 ...

The body of research on nirmatrelvir-ritonavir demonstrates a plethora of benefits in the treatment of COVID-19, and authors of a recent study identified more advantages to administering the treatment ...

Please provide your email address to receive an email when new articles are posted on . As the COVID-19 pandemic heads into its 4th year, it is a good time to reflect on strides made for those with ...

Meaningful reduction in symptoms seen for some taking an extended course outside of the context of an acute infection. HealthDay News — Extended-course nirmatrelvir/ritonavir yields a meaningful ...

Nirmatrelvir-ritonavir was beneficial for COVID-19 management in patients with chronic kidney disease or kidney failure, significantly reducing the risk of mortality and hospital admission. Paxlovid ® ...

In a recent study published in the NEJM, researchers presented the results of a phase III randomized controlled trial (RCT) of oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ...

The study of real-world evidence (RWE) found nearly 9 in 10 patients in a highly vaccinated cohort avoided hospitalization within 15 days of treatment for COVID-19. The study investigators said ...

Since its emergence at the end of 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, has infected almost 700 million individuals and claimed ...